MedTrace Logo

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

NCT05886634 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-10-20

No results posted yet for this study

Summary

Participants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread beyond its original location (advanced). In addition, their DDLS either has come back after treatment (recurrent), has spread to different parts of your body (metastatic), or is unable to be removed surgically (unresectable). The purpose of this study is to find out whether the combination of etrumadenant and zimberelimab is an effective treatment for people with advanced DDLS.

Conditions

  • Dedifferentiated Liposarcoma
  • Soft Tissue Sarcoma
  • Sarcoma,Soft Tissue
  • Sarcoma
  • Recurrent Dedifferentiated Liposarcoma
  • Unresectable Dedifferentiated Liposarcoma
  • Metastatic Dedifferentiated Liposarcoma

Interventions

DRUG

Etrumadenant

Will be administered PO daily for 24 weeks

DRUG

Zimberelimab

Will be administered IV every 2 weeks for 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Sandra D'Angelo, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-23
Primary Completion
2027-05-23
Completion
2027-05-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05886634 on ClinicalTrials.gov